Skip to main content
. 2021 Apr 20;8:626361. doi: 10.3389/fmed.2021.626361

Table 2.

Comparison of adherence, CPAP parameters, healthcare time, and overall costs between both groups.

UC group
(n = 58)
TM group
(n = 57)
Mean difference [95% CI], p-value
Adherence
Mean daily use of CPAP (min)
   Over the course of the first 3 months 262 [220; 305] (n = 50)* 288 [257; 319] (n = 51)* −25 [−77; 26], p = 0.34
   Over the course of the first 12 months 279 [237; 321] (n = 38)* 279 [247; 311] (n = 43)* 0 [−52; 52], 0.99
Proportion of patients discontinuing CPAP (n, %)
   At 3 months 8 (14%) 6 (11%) p = 0.59
   At 12 months 20 (34%) 14 (25%) p = 0.24
CPAP parameters at 1 year
   CPAP pressure (cmH2O) 11.4 [10.7; 12.1] 11.0 [10.4; 11.6] 0.4 [−0.5; 1.3], p = 0.35
   Residual AHI (events/h) 1.8 [1.0; 2.5] 1.7 [1.3; 2.1] 0.1 [−0.7; 0.9], p = 0.78
   Leaks at 95th percentile (L/min) 26 [20; 32] 24 [20; 27] 2 [−4; 8], p = 0.50
Healthcare time
   Total consultation time (min) 163 [147; 178] 178 [159; 197] −15 [−39; 9], p = 0.22
   Administrative time (min) 50 [45; 57] 56 [50; 62] −5 [−14; 3], p = 0.23
   Airview management time (min) NA 22 [19; 25] NA
Education-management time (min) 112 [101; 123] 99 [88; 112] 12 [−4; 27], p = 0.13
   Mean time per consultation (min) 33 [31; 34] 29 [28; 31] 3 [1; 6], p = 0.004
   Total consultation number (n) 5 [4.6; 5.5] 6.3 [5.6; 6.9] −1.2 [−2.1; −0.4], p = 0.003
   Face-to-face
consultation number (n)
4.8 [4.4; 5.3] 3.2 [2.9; 3.6] 1.6 [1.0; 2.2], p <0.001
Average cost (CHF) per patient
   Total 285 [259; 312] 248 [222; 274] 37 [0; 73], p = 0.047
   Sleep care givers salary 136 [123; 149] 148 [132; 164] −12 [−33; 8], p = 0.22
   Office room rental 121 [123; 149] 81 [71; 90] 40 [25; 55], p <0.001
   Public transportation 29 [26; 32] 19 [17; 22] 10 [6; 13], p <0.001

Data are displayed as means [95% CI] or proportions. Unpaired T-test or Chi-squared tests were performed.

NA, not applicable; AHI, apnoea–hypopnoea index; TM, telemedicine; UC, usual care.

*

The mean daily CPAP use is presented for patients still staying on follow-up visits at 3 or 12 months.